Would not surprise me.
The only recourse may be a class action lawsuit but there are many hoops to jump through to get one going.
Realistically, sadly-All got taken for a ride since legalization in Canada.
The insiders got rich while retail got screwed over.
Aleafia Health Inc.
85 Basaltic Rd
INVESTOR & MEDIA RELATIONS
All part of their plan and all part of the stock market game and related personal choices.
Was the insider who voted against the merger a person who benefits from this restructuring? If so, what is the recourse of the investors shut out with what seem to be now worthless holdings?
Aleafia Health Obtains Creditor Protection to Pursue Restructuring and Sale Process
Red White & Bloom and Aleafia Health Mutually Agree to Terminate Binding Letter Agreement
Aleafia Health Announces Fourth Quarter and Annual Financial Results
Revenue increased 9% to $11.7 million for the period ended March 31, 2023 (“Q4 FY2023”) versus $10.7 million for the period ended March 31, 2022
Net revenue increased 33% to $9.4 million for Q4 FY2023 versus $7.0 million for the period ended March 31, 2022
Revenue increased 24% to $57.4 million for the 12 months ended March 31, 2023 (“FY2023”) over the twelve months ended March 31, 2022
Net revenue increased 19% to $42.8 million for FY2023 over the twelve months ended March 31, 2022
#5 and #2 market share ranking in Divvy pre-roll and milled product formats in Q4 FY2023 in Ontario1
318% growth in international net revenue2 in FY2023 over the twelve months ended March 31, 2022
Third consecutive quarter of positive Adjusted EBITDA3 achieved in Q4 FY2023
Lets hope we all have luck in the future. :)
Split down the road ?
That is true.
Beats bankruptcy though.
though red white and bloom are no great shakes...
saved from imminent death. exposure to the US. it could have been a lot worse.
Is this sale a good thing long term?
Red White & Bloom and Aleafia Health Execute Binding Letter Agreement for Business Combination
200 day above the 50 and 2x the average volume on an up day. Our patience may soon be rewarded. I never assume anything in this industry but it looks promising
I think it is because they are in an industry that just started as legal in 2017 where they just got actual stores open 2 years ago and they sell a product nobody is allowed to advertise. The only people who can invest in the industry are retail investors because corporations and banks and hedge funds are not permitted in the OTC or cannabis touching businesses might be a few reasons as a start. Impatient people prefer the activity of trading. I have been investing in the cannabis industry since Tweed went public. Made a bunch there and have redeployed my $ into this industry on a more diversified basis. The large LPs are a joke now. Constellation trashed Canopy. Glad I got out when the takeover happened. IMO the best bet in Canada is in Aleafia because they understand CPG is the future. I am watching a couple of other names but Aleafia is the only Cdn LP I own at the moment This is a nascent global industry that offers a product that is so beneficial people are willing to risk prison for. In my opinion this is the greatest opportunity to make generational wealth I will see in my lifetime. I hope that clarifies the situation. Not a normal industry. That is why it is such an extreme opportunity.
Sounds real good. So why are in the three cent range ?
They have been doing what they say they will. I have family that is a patient and what they say about the products is true.
Aleafia Health Announces Q3 FY2023 Results, International Expansion and Second Quarter of Profitability
I'm happy someone is enabling Aleafia to stay in business.
Aleafia Health to Announce Fiscal Year 2023 Third Quarter Results
Thanks ... An inch at a time ... Aleafia Health Announces New International Partner, Strengthening Connections in High-Potential European Market
New Board Chair Also Named
TORONTO, January 30, 2023 – Aleafia Health Inc. (TSX: AH, OTCQB: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce that it has signed a new European cannabis distribution partner, representing a one-year, approximately $1 million contract, significantly bolstering the Company’s record $1.2 million year-to-date sales in its growing international channel.
“This new announcement is very significant: it builds upon advancements made in August 2022 when the Company revealed a two-year $4.6 million European sales commitment and broadens our international reach,” said Aleafia CEO Tricia Symmes. “The Company is involved in overseas markets because international success leverages both its products and brands, and the addressable European cannabis market is high potential, so this relationship provides another gateway into further European expansion in the medical and potential recreational markets.”
“These international agreements are an important part of our strategic plan for growth and profitability,” said Matt Sale, CFO. “These activities grow revenue, are not subject to excise duties, lock in attractive margins, and improve our overall cash conversion cycle and net working capital performance, continuing to deliver against one of our core sale pillars for FY 2023.”
David Pasieka Replaces Mark Sandler as Aleafia Health Board Chair
The Company also announced that David Pasieka, a director since September 2021, will become its Board Chair, following the January 30th retirement of Mark Sandler, who has served as Chair since July 2021 and is Aleafia Health’s longest serving director having being appointed in 2018. Pasieka, a seasoned public company executive, with extensive formal and board level experience, has served on Aleafia’s FAC and HRC committees and currently serves on the Board of Oakville Hydro / Oakville Enterprise Corporation as well as serving on the Faculty of the Caribbean Governance Institute.
“The Company has been very grateful for Mark Sandler’s counsel and support of the vision for the future as we transitioned from a bulk wholesale cannabis provider into a branded adult-use, medical and international producer. Under his guidance, the Company consistently increased market share, achieved a top 10 standing in multiple formats and markets for Divvy, negotiated the amendment of its $37.3 Million Convertible Debentures while securing a $5.6 million equity financing in June 2022,” said Symmes. “Since becoming CEO in February 2022, I benefited from Mark’s thoughtful insights in our concerted drive toward Adjusted breakeven EBITDA profitability, which was achieved two quarters ahead of projections. Now David Pasieka will build on those accomplishments, guiding us to further growth and enhanced profitability.”
For Investor & Media Relations
Matthew Sale, CFO
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
The Company is a federally licensed Canadian cannabis company offering cannabis products in Canadian adult-use and medical markets and in select international markets, including Australia and Germany. The Company operates a virtual medical cannabis clinic staffed by physicians and nurse practitioners which provide health and wellness services across Canada.
The Company owns three licensed cannabis production facilities and operates a strategically located distribution centre all in the province of Ontario, including the largest, outdoor cannabis cultivation facility in Canada. The Company produces a diverse portfolio of cannabis and cannabis derivative products including dried flower, pre-roll, milled, vapes, oils, capsules, edibles, sublingual strips, and topicals.
Cautionary Statement on Non-IFRS Measures
Adjusted EBITDA is not a recognized financial measure under IFRS, does not have a standardized meaning and therefore may not be comparable to similar measures presented by other issuers. For additional information including the definition and purpose of the non-IFRS measure, see “Cautionary Statement re Non-IFRS measures” in the Company’s Management’s Discussion and Analysis for the period ended September 30, 2022 found on SEDAR at www.sedar.com.
Forward Looking Information Cautionary Statement
Certain statements herein relating to the Company constitute “forward looking information”, within the meaning of applicable securities laws, including without limitation, statements regarding the value of contracts. Such forward-looking statements involve unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward looking statements include, but are not limited to, statements with respect to our long term profitability, market share, net revenue, branded cannabis net revenue, Adjusted EBITDA, projected value of contracts and other financial outlook projections for fiscal year 2023, our commercial operations, including production and / or sales of cannabis, quantities of future cannabis production, anticipated revenue in connection with such sales, and other Information that is based on forecasts of future results, estimates of production not yet determinable, and other key management assumptions. The following material factors or assumptions were used to develop the forward looking information: Aleafia’s ability to cultivate, harvest and deliver sufficient flower compliant with regulatory and contractual specifications to meet demand, our new European partner will purchase the minimum quantity contractually required to maintain its exclusivity rights, information provided by our new European partner on their future purchasing plans is accurate, our new European customer will comply with its contractual commitments, Euro to Canadian collar currency conversion rates and costs remain stable, market size and growth of the Canadian adult-use and medical cannabis markets and international markets, retail store penetration, script trends, cultivation and processing capacity, costs of production, gross and net revenue per gram. Actual results may differ materially from those expressed or implied by such forward looking statements and involve risk and uncertainties relating to: currency conversion costs, value of foreign and Canadian currencies, future cultivation yield and quality, actual operating performance of facilities, product launches, facility licenses and amendments, average selling prices, cost of goods sold, operating expenses, Adjusted EBITDA, regulatory changes in the Canadian and international markets, and other uninsured risks. The forward looking information was approved by Management as of January 10, 2023. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. The forward looking information is provided for information purposes only and readers are cautioned that it may not be appropriate for other purposes. This presentation is provided for general information purposes only and does not constitute an offer to sell or solicitation of an offer to buy any security in any jurisdiction.
Aleafia Health Announces New International Partner, Strengthening Connections in High-Potential European Market
Aleafia Health Successfully Completes TSX Review and Announces Entry into Fifth Province
If I was buying and flipping I could have made money. This is a sad one.
Aleafia Health Announces Achieving Major Profitability Milestone Ahead of Target and $10.6 Million Total Net Revenue in Q2 FY2023
I jumped back in nicely recently as the PPS was hard to resist.
My research into the sales in my local dispensary’s (and my personal experiences with their product lines) led me to do so.
Aleafia Health to Announce Fiscal Year 2023 Second Quarter Results
TORONTO, November 2, 2022 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) will announce on November 9 prior to market open its fiscal year 2023 second quarter results for the period ending September 30, 2022. The Company will also host its earnings conference call the same day at 8:30 a.m. EST. The call will be hosted by CEO Tricia Symmes and CFO Matt Sale.
CONFERENCE CALL & WEBCAST
Date: November 9, 2022
Time: 8:30 a.m. EST
Phone Registration Link
This conference call will be webcast live over the internet and can be accessed through the link provided above. Audio of the call will be available to participants through both the conference call line and webcast; however, the presentation may only be viewed via the webcast. Participants who miss the live call can view a replay at any time via the link provided.
For Investor & Media Relations:
Matthew Sale, CFO
LEARN MORE: www.AleafiaHealth.com
Aleafia Health Expands Sunday Market House of Brands With Coveted Lineup of Winter Product Launches
I am holding and buying more. Imo it is the best play in Canada atm. They are gaining market share and offering new products while the “big” names are slipping. I was considering an exit in the summer but they renegotiated with their lenders who accepted a deal with a price higher than market at the time. It is not possible to apply the same metrics to an emerging market as to a mature one. I have averaged down and honestly think this has a shot at success. Their medical line is expanding and divy sells well according to my local dispensary. Not all my picks are going to make it but I do think this one has a shot.
Haven’t checked in for a while.
Sad to see how corporate mismanagement has decimated the PPS over the past year or two.
I hope there is a turnaround at some point before declaring bankruptcy is necessary.
I have used and used their products and have no complaints with them.
The blame rests on the BOD only.
Why isn't there a chart for half of the companies since the change of the ihub platform? It sucks now I am really disappointed with ihub now. I got great info and was able to get great insights from other users till that change. I will not be renewing my paid participation after this year. I will not pay to be disappointed lol!
Aleafia Health Announces Results of Annual General Meeting
TORONTO, September 29, 2022 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce the results of the vote on the election of directors at its annual meeting of shareholders held on September 27, 2022 (the “Meeting”). All six nominees set out in the management information circular of the Company dated August 19, 2022 were elected to the board of directors (the “Board”) of the Company.
Nominee For Against Withheld Non Vote For Against Withheld
Mark Sandler 67,007,871 1,632,272 0 23,208,803 97.62% 2.38% 0.00%
Luciano Galasso 67,165,098 1,475,045 0 23,208,803 97.85% 2.15% 0.00%
Ian Troop 67,240,952 1,399,191 0 23,208,803 97.96% 2.04% 0.00%
David Pasieka 67,167,928 1,472,215 0 23,208,803 97.86% 2.14% 0.00%
Jon Pereira 67,185,790 1,454,353 0 23,208,803 97.88% 2.12% 0.00%
Carlo Sistilli 67,209,871 1,430,272 0 23,208,803 97.92% 2.08% 0.00%
Final voting results on all matters will be filed on the Company’s SEDAR profile at www.sedar.com.
For Investor & Media Relations:
Matthew Sale, CFO
LEARN MORE: www.AleafiaHealth.com